Literature DB >> 29721733

Time between suspected and confirmed diagnoses of Crohn's disease and ulcerative colitis in patients followed in gastroenterological practices in Germany.

Karel Kostev1, Marcel Konrad2, Louis Jacob3.   

Abstract

AIMS: The goal of the present study was to analyze the time between suspected and confirmed diagnoses of Crohn's disease (CD) and ulcerative colitis (UC) in patients followed in gastroenterological practices in Germany.
METHODS: The study included individuals who received a suspected diagnosis of CD or UC (index date) and were followed in 47 gastroenterological practices in Germany between January 2007 and December 2016. The main outcome measure of the study was the time between suspected and confirmed diagnoses of CD and UC. Covariables included age, sex, and type of health insurance (private or statutory). A multivariate linear regression model was used to analyze the impact of the different variables on the time between suspected and confirmed diagnoses of CD and UC.
RESULTS: The study included 2657 patients with a suspected diagnosis of CD and UC between 2007 and 2016. The mean age was 39.7 (SD 15.9) and 41.3 (16.8) in the CD and UC groups, respectively. Median time between suspected and confirmed diagnoses was 46 days in the CD group and 43 days in the UC group. Median time ranged from 8 to 112 days in the different gastroenterology practices and was significantly shorter in individuals with private health insurance coverage than in those with statutory health insurance.
CONCLUSIONS: Median time between suspected and confirmed diagnoses of CD or UC was around 45 days in patients followed in gastroenterological practices in Germany. Health insurance was the only factor to have a significant impact on this time.

Entities:  

Keywords:  Crohn’s disease; Gastroenterological practices; Risk factors; Time between suspected and confirmed diagnoses; Ulcerative colitis

Mesh:

Year:  2018        PMID: 29721733     DOI: 10.1007/s00384-018-3068-9

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  14 in total

1.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

Authors:  Geert D'Haens; Filip Baert; Gert van Assche; Philip Caenepeel; Philippe Vergauwe; Hans Tuynman; Martine De Vos; Sander van Deventer; Larry Stitt; Allan Donner; Severine Vermeire; Frank J Van De Mierop; Jean-Charles R Coche; Janneke van der Woude; Thomas Ochsenkühn; Ad A van Bodegraven; Philippe P Van Hootegem; Guy L Lambrecht; Fazia Mana; Paul Rutgeerts; Brian G Feagan; Daniel Hommes
Journal:  Lancet       Date:  2008-02-23       Impact factor: 79.321

2.  Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.

Authors:  Jean Frédéric Colombel; Paul Rutgeerts; Walter Reinisch; Dirk Esser; Yanxin Wang; Yinghua Lang; Colleen W Marano; Richard Strauss; Björn J Oddens; Brian G Feagan; Stephen B Hanauer; Gary R Lichtenstein; Daniel Present; Bruce E Sands; William J Sandborn
Journal:  Gastroenterology       Date:  2011-06-30       Impact factor: 22.682

3.  Diagnostic Delay in Crohn's Disease: Time for Red Flags.

Authors:  Gionata Fiorino; Silvio Danese
Journal:  Dig Dis Sci       Date:  2016-09-16       Impact factor: 3.199

4.  Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease.

Authors:  Stephan R Vavricka; Sabrina M Spigaglia; Gerhard Rogler; Valérie Pittet; Pierre Michetti; Christian Felley; Christian Mottet; Christian P Braegger; Daniela Rogler; Alex Straumann; Peter Bauerfeind; Michael Fried; Alain M Schoepfer
Journal:  Inflamm Bowel Dis       Date:  2011-04-20       Impact factor: 5.325

5.  Diagnostic delay in Canadian children with inflammatory bowel disease is more common in Crohn's disease and associated with decreased height.

Authors:  Amanda Ricciuto; Jennifer R Fish; Diane E Tomalty; Nicholas Carman; Eileen Crowley; Cynthia Popalis; Aleixo Muise; Thomas D Walters; Anne M Griffiths; Peter C Church
Journal:  Arch Dis Child       Date:  2017-08-09       Impact factor: 3.791

6.  Frequency of Thyroid-Stimulating Hormone Monitoring in Patients After Thyroidectomy: A Retrospective Study in Primary Care Practices in Germany.

Authors:  Karel Kostev; Margarethe Winiarski; Lisa Schüller; Andreas M Sesterhenn; Louis Jacob
Journal:  Exp Clin Endocrinol Diabetes       Date:  2018-02-02       Impact factor: 2.949

Review 7.  Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.

Authors:  Siew C Ng; Hai Yun Shi; Nima Hamidi; Fox E Underwood; Whitney Tang; Eric I Benchimol; Remo Panaccione; Subrata Ghosh; Justin C Y Wu; Francis K L Chan; Joseph J Y Sung; Gilaad G Kaplan
Journal:  Lancet       Date:  2017-10-16       Impact factor: 79.321

8.  The Time Course of Diagnostic Delay in Inflammatory Bowel Disease Over the Last Sixty Years: An Italian Multicentre Study.

Authors:  Laura Cantoro; Antonio Di Sabatino; Claudio Papi; Giovanna Margagnoni; Sandro Ardizzone; Paolo Giuffrida; Diana Giannarelli; Alessandro Massari; Rita Monterubbianesi; Marco Vincenzo Lenti; Gino Roberto Corazza; Anna Kohn
Journal:  J Crohns Colitis       Date:  2017-08-01       Impact factor: 9.071

9.  Potential delay in the diagnosis of vulvar cancer and associated risk factors in women treated in German gynecological practices.

Authors:  Jennifer Muigai; Louis Jacob; Konstantinos Dinas; Karel Kostev; Matthias Kalder
Journal:  Oncotarget       Date:  2018-01-03

10.  Diagnostic delay in inflammatory bowel disease increases the risk of intestinal surgery.

Authors:  Dong-Won Lee; Ja Seol Koo; Jung Wan Choe; Sang Jun Suh; Seung Young Kim; Jong Jin Hyun; Sung Woo Jung; Young Kul Jung; Hyung Joon Yim; Sang Woo Lee
Journal:  World J Gastroenterol       Date:  2017-09-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.